Rein Therapeutics Files 8-K on Agreements and Equity Sales
Ticker: RNTX · Form: 8-K · Filed: Apr 22, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, name-change
TL;DR
Rein Therapeutics filed an 8-K detailing material agreements and equity sales.
AI Summary
Rein Therapeutics, Inc. (formerly Aileron Therapeutics, Inc.) filed an 8-K on April 22, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and financial statements. The company, located in Austin, Texas, changed its name on March 29, 2024.
Why It Matters
This filing indicates potential new business dealings and equity transactions for Rein Therapeutics, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — Filings related to material definitive agreements and unregistered equity sales can signal significant corporate actions that may carry inherent risks.
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Registrant
- Aileron Therapeutics, Inc. (company) — Former company name
- April 21, 2025 (date) — Earliest event reported
- April 22, 2025 (date) — Date of report
- March 29, 2024 (date) — Date of name change
- 12407 N. Mopac Expy., Suite 250, #390 Austin, Texas 78758 (address) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement mentioned in the filing?
The filing indicates an 'Entry into a Material Definitive Agreement' as an item of disclosure, but the specific details of the agreement are not provided in this summary.
What type of equity securities were sold unregistered?
The filing lists 'Unregistered Sales of Equity Securities' as a reported item, but the specific type and details of these securities are not elaborated upon in this summary.
When did Rein Therapeutics officially change its name from Aileron Therapeutics, Inc.?
Rein Therapeutics, Inc. changed its name from Aileron Therapeutics, Inc. on March 29, 2024.
What is the primary business of Rein Therapeutics, Inc. according to its SIC code?
Rein Therapeutics, Inc. is classified under Pharmaceutical Preparations [2834].
What is the address of Rein Therapeutics' principal executive offices?
The principal executive offices of Rein Therapeutics are located at 12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 22, 2025 regarding Rein Therapeutics, Inc. (RNTX).